NCT02442648View on ClinicalTrials.gov

B-Cell Targeted Carfilzomib Desensitization

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 30, 2021

Study Completion Date

September 30, 2021

Conditions
Transplants and Implants
Interventions
DRUG

Carfilzomib

Carfilzomib will be administered for desensitization per study protocol.

DRUG

Rituximab

Rituximab will be administered for desensitization per study protocol.

Trial Locations (2)

45219

RECRUITING

The Christ Hospital, Cincinnati

45267

RECRUITING

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

E. Steve Woodle

OTHER